Skip header and navigation

10 records – page 1 of 1.

Cinacalcet (Sensipar) for secondary hyperparathyroidism in chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35371
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1465
Available Online
View Pamphlet
Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinac…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Cinacalcet
Renal Insufficiency, Chronic - drug therapy
Hyperparathyroidism, Secondary - drug therapy
Subjects (LCSH)
Chronic renal failure
Hyperparathyroidism
Kidneys--Diseases--Treatment
Abstract
Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinacalcet, possible side effects, and how to store this medication.
Notes
Previous title: Sensipar (Cinacalcet) to treat secondary hyperparathyroidism in chronic kidney disease
Previous title: Cinacalcet (Sensipar) to treat secondary hyperparathyroidism in chronic kidney disease (CKD)
Responsibility
Prepared by: Renal Program
Pamphlet Number
1465
Less detail

Dalteparin (Fragmin) to prevent clotting during hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams35807
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1760
Available Online
View Pamphlet
Dalteparin is a medication that is part of a group of drugs called blood thinners. Fragmin® is the brand name of dalteparin. During hemodialysis your blood passes through the dialysis blood lines and a dialyzer (artificial kidney), which can cause clots to form. Dalteparin stops clots from forming. This pamphlet explains how to take dalteparin, possible side effects, and symptoms that you should mention to your nurse.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Dalteparin
Renal Dialysis
Subjects (LCSH)
Hemodialysis
Blood--coagulation
Specialty
Nephrology
Abstract
Dalteparin is a medication that is part of a group of drugs called blood thinners. Fragmin® is the brand name of dalteparin. During hemodialysis your blood passes through the dialysis blood lines and a dialyzer (artificial kidney), which can cause clots to form. Dalteparin stops clots from forming. This pamphlet explains how to take dalteparin, possible side effects, and symptoms that you should mention to your nurse.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1760
Less detail

Déclenchement artificiel du travail et maturation cervicale au moyen de comprimés oraux de misoprostol (prostaglandine E1) (Cytotec)

https://libcat.nshealth.ca/en/permalink/chpams35880
Nova Scotia Health Authority. Yarmouth Regional Hospital. Women and Children's Health Unit. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1816
Available Online
View Pamphlet
Le misoprostol est une pilule qui contient un médicament appelé prostaglandine E1. La prostaglandine E1 assouplit le col de l’utérus pour le préparer au travail et déclencher des contractions. Cytotec® est le nom de marque de ce médicament. Le présent dépliant explique à quoi s'attendre si vous prenez du misoprostol, les complications possibles et quand informer un membre de votre équipe de soins de santé. ; This pamphlet is a French translation of "Induction of Labour and Cervical Ripening wit…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Yarmouth Regional Hospital. Women and Children's Health Unit
Alternate Title
Induction of labour and cervical ripening with oral misoprostol (prostaglandin E1) (Cytotec®)
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
French
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Labor, Induced
Cervical Ripening
Misoprostol
Subjects (LCSH)
Labor (Obstetrics)
Specialty
Gynecology
Abstract
Le misoprostol est une pilule qui contient un médicament appelé prostaglandine E1. La prostaglandine E1 assouplit le col de l’utérus pour le préparer au travail et déclencher des contractions. Cytotec® est le nom de marque de ce médicament. Le présent dépliant explique à quoi s'attendre si vous prenez du misoprostol, les complications possibles et quand informer un membre de votre équipe de soins de santé.
This pamphlet is a French translation of "Induction of Labour and Cervical Ripening with Oral Misoprostol (Prostaglandin E1) (Cytotec®)" pamphlet 1771. Misoprostol is a pill that contains a medication called prostaglandin E1. Prostaglandin E1 softens the cervix to get it ready for labour and to cause labour contractions. Cytotec® is the brand name of this medication. This pamphlet explains what to expect when you get misoprostol, possible complications of misoprostol, and when you should notify a member of your health care team.
Responsibility
Prepared by: Women and Children's Health Unit
Pamphlet Number
1816
Less detail

Induction of labour and cervical ripening with oral misoprostol (prostaglandin E1) (Cytotec)

https://libcat.nshealth.ca/en/permalink/chpams35821
Nova Scotia Health Authority. Women and Children's Health. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1771
Available Online
View Pamphlet
Misoprostol is a pill that contains a medication called prostaglandin E1. Prostaglandin E1 softens the cervix to get it ready for labour and to cause labour contractions. Cytotec® is the brand name of this medication. This pamphlet explains what to expect when you get misoprostol, possible complications of misoprostol, and when you should notify a member of your health care team. The French version of this pamphlet 1816, "Déclenchement artificiel du travail et maturation cervicale au moyen de c…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Women and Children's Health
Alternate Title
Induction of labor and cervical ripening with oral misoprostol (prostaglandin E1) (Cytotec)
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Labor, Induced
Cervical Ripening
Misoprostol
Subjects (LCSH)
Labor (Obstetrics)
Specialty
Gynecology
Abstract
Misoprostol is a pill that contains a medication called prostaglandin E1. Prostaglandin E1 softens the cervix to get it ready for labour and to cause labour contractions. Cytotec® is the brand name of this medication. This pamphlet explains what to expect when you get misoprostol, possible complications of misoprostol, and when you should notify a member of your health care team. The French version of this pamphlet 1816, "Déclenchement artificiel du travail et maturation cervicale au moyen de comprimés oraux de misoprostol (prostaglandine E1) (Cytotec®)", is also available.
Responsibility
Prepared by: Women and Children's Health Unit
Pamphlet Number
1771
Less detail

Intravenous Immunoglobulin (IVIG)

https://libcat.nshealth.ca/en/permalink/chpams36584
Nova Scotia Health Authority. QEII. Perioperative Blood Management Service. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1247
Available Online
View Pamphlet
IVIG is a collection of antibodies. Antibodies help your body fight infection. IVIG comes from the plasma (part of the blood) of thousands of different donors. IVIG is available under many brand names (like Gamunex®, IGIVnex®, Gammagard Liquid®, and others). This pamphlet explains how IVIG is given, benefits, and possible side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. QEII. Perioperative Blood Management Service
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Immunoglobulins, Intravenous
Autoimmune Diseases - drug therapy
Subjects (LCSH)
Immunoglobulins
Autoimmune diseases
Specialty
Hematology
Abstract
IVIG is a collection of antibodies. Antibodies help your body fight infection. IVIG comes from the plasma (part of the blood) of thousands of different donors. IVIG is available under many brand names (like Gamunex®, IGIVnex®, Gammagard Liquid®, and others). This pamphlet explains how IVIG is given, benefits, and possible side effects.
Responsibility
Prepared by: Perioperative Blood Management Service
Pamphlet Number
1247
Less detail

Lanthanum (Fosrenol) and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35370
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1466
Available Online
View Pamphlet
Lanthanum (LAN-tha-num) is a medication used to lower the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Lanthanum
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
Lanthanum (LAN-tha-num) is a medication used to lower the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra phosphorus, but you may need a medication like lanthanam to remove more. Fosrenol® is the brand name for lanthanum. This pamphlet explains how to take lanthanum, possible side effects, and how to store this medication.
Notes
Previous title: Fosrenol (Lanthanum) and hemodialysis
Responsibility
Prepared by: Renal Program
Pamphlet Number
1466
Less detail

One-Alpha® (alfacalcidol) and hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams36672
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1470
Available Online
View Pamphlet
One-Alpha® is a medication with the active ingredient alfacalcidol. This is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. Alfacalcidol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can ca…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Pharmacy Services
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
One-Alpha® is a medication with the active ingredient alfacalcidol. This is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. Alfacalcidol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can cause low calcium levels of in the blood and weaker bones. One-Alpha® raises the amount of vitamin D in your body that can be used. How to take the medication, side effects to watch for, and how to store it are reviewed. One-Alpha® is a brand name for alfacalcidol.
Responsibility
Prepared by: Renal Pharmacy Team, Renal Program
Pamphlet Number
1470
Less detail

Rocaltrol® (calcitriol) and hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams36671
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1468
Available Online
View Pamphlet
Rocaltrol® is a medication with the active ingredient calcitriol. This is a form of vitamin D that can be used by the body. Calcitriol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can cause low calcium levels in the blood and weaker bones. Rocaltrol raises the amoun…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Pharmacy Services
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Calcitriol
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
Rocaltrol® is a medication with the active ingredient calcitriol. This is a form of vitamin D that can be used by the body. Calcitriol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can cause low calcium levels in the blood and weaker bones. Rocaltrol raises the amount of vitamin D in your body that can be used. How to take the medication, side effects to watch for, and how to store it are reviewed. Rocaltrol® is a brand name for calcitriol.
Responsibility
Prepared by: Renal Pharmacy Team, Renal Program
Pamphlet Number
1468
Less detail

Sevelamer (Renagel) and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35372
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1464
Available Online
View Pamphlet
Sevelamer (se-VEL-a-mer) is a medication that lowers the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Sevelamer binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra ph…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Sevelamer
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Subjects (LCSH)
Hemodialysis
Chronic renal failure
Kidneys--Diseases--Treatment
Abstract
Sevelamer (se-VEL-a-mer) is a medication that lowers the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Sevelamer binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra phosphorus, but you may need a medication like sevelamer to remove more. Renagel® is one brand name for sevelamer. This pamphlet explains how to take sevelamer, possible side effects, and how to store this medication.
Notes
Previous title: Renagel (Sevelamer) and Hemodialysis
Responsibility
Prepared by: Renal Program
Pamphlet Number
1464
Less detail

Ustekinumab (Stelara) therapy

https://libcat.nshealth.ca/en/permalink/chpams35722
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1695
Available Online
View Pamphlet
Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taki…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (10 p.) : digital, PDF file
Subjects (MeSH)
Ustekinumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Ulcerative colitis
Specialty
Medications
Abstract
Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taking ustekinumab and while you are taking it are listed. Possible side effects, information about pregnancy and breast/chest feeding, and other important things to know are included.
Notes
Previous title: Ustekinumab (Stelara) therapy for Crohn's disease
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1695
Less detail

10 records – page 1 of 1.